Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
96.993,62
-0,22%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Tourmaline Bio Inc (TRML) Tourmaline Bio Inc (TRML) Notizie

Tourmaline Bio Inc

TRML
20,65
0,31 (1,52%)
21 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/12/202422:08EDGAR2Form 8-K - Current report
10/12/202414:44EDGAR2Form 8-K - Current report
10/12/202414:30GLOBETourmaline Bio Highlights Cardiovascular Inflammation Focus..
14/11/202423:05EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202415:45EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202413:30GLOBETourmaline Bio to Host Investor Day on Tuesday, December 10,..
08/11/202420:17EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
07/11/202423:21EDGAR2Form S-3 - Registration statement under Securities Act of..
07/11/202414:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202413:37EDGAR2Form 8-K - Current report
07/11/202413:30GLOBETourmaline Bio Reports Third Quarter 2024 Financial Results..
31/10/202412:30GLOBETourmaline Bio to Present at Upcoming Investor Conferences
15/10/202413:30GLOBETourmaline Bio to Host Expert Webinar on Human Genetic..
11/10/202413:30GLOBETourmaline Bio to Showcase Two Poster Presentations at the..
10/10/202422:25EDGAR2Form 8-K - Current report
08/10/202413:30GLOBETourmaline Bio Announces Formation of Cardiovascular..
11/9/202422:18EDGAR2Form 8-K - Current report
05/9/202422:19EDGAR2Form 8-K - Current report
03/9/202413:45GLOBETourmaline Bio to Present at Upcoming Investor Conferences
22/8/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202400:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202414:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202413:44EDGAR2Form 8-K - Current report
08/8/202413:30GLOBETourmaline Bio Reports Second Quarter 2024 Financial Results..
02/8/202422:30GLOBETourmaline Bio Presents Phase 2 TRANQUILITY Study Design at..
27/6/202414:05GLOBETourmaline Bio Announces the Promotion of Ryan Robinson to..
07/6/202422:04EDGAR2Form 8-K - Current report
07/6/202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202413:10GLOBETourmaline Bio to Present at the Jefferies Global Healthcare..
16/5/202413:00GLOBETourmaline Bio Initiates Clinical Development of TOUR006 for..
13/5/202422:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202413:15EDGAR2Form 8-K - Current report
13/5/202413:00GLOBETourmaline Bio Reports First Quarter 2024 Financial Results..
02/4/202413:00GLOBEAvalo Therapeutics Appoints Biotech Leaders to Board of..
19/3/202412:00GLOBETourmaline Bio Reports Fourth Quarter and Full Year 2023..
27/2/202413:30GLOBETourmaline Bio to Present at Upcoming Investor Conferences
15/2/202403:08EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202402:51EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/2/202422:22EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01/2/202414:00GLOBETourmaline Bio to Present at the Guggenheim Healthcare Talks..
29/1/202422:01GLOBETourmaline Bio Announces Closing of $172.5 Million Public..
26/1/202422:12EDGAR2Form 8-K - Current report
26/1/202422:08EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
25/1/202413:00GLOBETourmaline Bio Announces Pricing of Public Offering of..
25/1/202403:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
24/1/202423:10EDGAR2Form 8-K - Current report
24/1/202422:05GLOBETourmaline Bio Announces Proposed Public Offering of Common..
08/1/202415:19EDGAR2Form 8-K - Current report
08/1/202413:00GLOBETourmaline Bio Announces Expected Upcoming Key Milestones..
Apertura: 20,22 Min: 20,20 Max: 21,53
Chiusura: 20,34

La tua Cronologia

NASDAQ
TRML
Tourmaline Bio
BIT
S29006
Societe Generale Effekten
AMEX
SPVM
Invesco S&P 500 Value wi...
BOV
F1SL34M
Fastly
NASDAQ
ASTSW
AST SpaceMobile
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network